Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
Ki-67 Grade and Lu-177 DOTATATE Eligibility in GEP-NET
Your Ki-67 grade is one of the first numbers a PRRT team reviews when you have a GEP-NET. This article explains what each grade means for Lu-177 DOTATATE eligibility - and what to do if your case falls in a gray zone.
Erectile Dysfunction After Lu-177 PSMA Therapy
Erectile dysfunction is one of the most common concerns men with mCRPC raise during Lu-177 PSMA therapy - but it is rarely the therapy itself that is the primary cause. This article explains why ED is so widespread at this stage, what a realistic recovery timeline looks like, and what management strategies may help protect intimacy.
Lu-177 PSMA Therapy for Bone Pain in Advanced Prostate Cancer
Bone metastases are among the most painful aspects of advanced prostate cancer. Research suggests that Lu-177 PSMA therapy may relieve bone pain in eligible men with mCRPC - here is what the evidence shows and who may benefit.
Coordinating Your Parent's Lu-177 PSMA Treatment in India
If your parent has mCRPC and someone has mentioned Lu-177 PSMA therapy in India as a possible next step, this eight-step checklist walks you through every coordination task - from gathering the right scans to managing radiation safety at home between cycles.
Lu-177 PSMA Therapy for Your Father After Chemo
If your father has metastatic prostate cancer and chemotherapy has stopped working, Lu-177 PSMA therapy may be the next step worth understanding. This guide covers eligibility, what the evidence shows, and exactly what to bring to his next oncology appointment.
PRRT in India for South Asian GEP-NET Patients
Patients with GEP-NETs from Pakistan, Bangladesh, and Sri Lanka are increasingly traveling to India for PRRT. This guide covers real costs, the step-by-step treatment timeline, and visa logistics for each country.
PRRT After Somatostatin Analogue Failure in GEP-NET
If your GEP-NET has grown while you were on octreotide or lanreotide, lutetium Lu-177 dotatate PRRT may be the next option to explore. Here is what the clinical evidence shows and how to know whether you qualify.
What to Expect 3-6 Months After Lu-177 PSMA Therapy
Finished your last cycle of lutetium Lu-177 vipivotide tetraxetan for mCRPC? This guide covers the blood tests, scans, PSA trends, and symptoms to expect in the 3 to 6 months after treatment ends.
Why Lu-177 PSMA Works After Chemotherapy Fails
Lu-177 PSMA therapy works on a different principle from standard chemotherapy - it delivers radiation directly into prostate cancer cells by targeting the PSMA protein they overproduce. This article explains the mechanism, what the VISION trial evidence shows, and who may be eligible after chemo has stopped working.
Lu-177 PSMA Treatment Cost in India vs US vs UK
Out-of-pocket costs for Lu-177 PSMA therapy differ sharply between India, the US, and the UK private sector. Here is what published data shows, and what to check before planning any treatment trip.
How to Get a PRRT Second Opinion Before Travelling to India
Before you book a flight to India for PRRT, a remote Ga-68 DOTATATE eligibility review can tell you whether you are likely to qualify - and what to do if you are not. Here is what the process involves and what documents you need.
PSA Doubling Time and Lu-177 PSMA Treatment Timing
If your PSA keeps rising despite hormone therapy, PSA doubling time is one of the clearest signals that a treatment reassessment is due. This article explains what PSADT means for men with mCRPC and when to ask about Lu-177 PSMA therapy.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.